https://www.youtube.com/watch?v=XjUTvtvS0vE
Thomas Tuschl invented a gene-silencing technique called RNA interference (RNAi) that has used in medicine. With this invention successfully commercialised,

https://www.rockefeller.edu/news/35625-how-one-scientists-fascination-with-rna-changed-medicine-forever/
Three patents came from this miRNA research, all named after him. Tuschl I covers 14 methods of inducing RNAi using specific lengths of double-stranded RNA—and led to his co-founding of the pharmaceutical company Alnylam—while Tuschl II focuses on the compositions, methods, and uses of siRNAs in the development of RNAi therapeutics. Tuschl

https://www.rockefeller.edu/our-scientists/heads-of-laboratories/911-thomas-tuschl/
The Tuschl lab has developed approaches to precisely define the binding sites of RNPs and RBPs on RNA and its precursors. Past studies focused on characterizing RBPs implicated in genetic diseases such as fragile X syndrome as well as those with unknown functions. Current studies identify RBPs and the enzymes required for ribosome-associated

https://en.wikipedia.org/wiki/Thomas_Tuschl
Thomas Tuschl (born 1 June 1966) is a German biochemist and molecular biologist, known for his research on RNA. Biography Tuschl ... Possible future applications of this method include treatment of tumors or genetic disorders. The function of certain genes can be studied more easily. RNA interference is a major step in genetics.

http://lab.rockefeller.edu/tuschl/
Thomas Tuschl studies the role of RNA-binding proteins (RBPs) and noncoding RNAs (ncRNAs) in post-transcriptional gene regulation in human cells. ... Nucleo-cytoplasmic shuttling RNA-binding proteins (current research) RNA fluorescence in-situ hybridization The Rockefeller University | 1230 York Avenue, New York, NY 10065 | 212-327-8000

https://www.rockefeller.edu/news/1302-tenure-awarded-to-rna-researcher-thomas-tuschl-3/
Dr. Tuschl's research focuses on RNA interference (RNAi), the process by which small RNA molecules interfere with gene expression. For many years, RNAs were seen simply as vehicles that transport genetic information from the nucleus to the site of protein synthesis, but it has become obvious that particular small RNA molecules can regulate

https://scholar.google.com/citations?user=DBU5a2QAAAAJ
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. SM Elbashir, J Harborth, W Lendeckel, A Yalcin, K Weber, T Tuschl. nature 411 (6836), 494-498. , 2001. 14171. 2001. Identification of novel genes coding for small expressed RNAs.

https://www.genomeweb.com/rnai/new-position-rockefeller-tuschl-speaks-rnai-and-its-future
At A Glance. Name: Tom Tuschl Age: 37 Associate Professor and Head of laboratory for RNA molecular biology at Rockefeller University. Background: The Max Planck Institute for Biophysical Chemistry, Department of Cellular Biochemistry — 1999-2002 Whitehead Institute for Biomedical Research; MIT, Department of Biology — 1995-1999

https://lab.rockefeller.edu/tuschl/research
Thomas Tuschl studies the role of RNA-binding proteins (RBPs) and noncoding RNAs (ncRNAs) in post-transcriptional gene regulation in human cells. He develops genome-wide approaches for the characterization of mRNA-RBP and mRNA-ncRNA interaction networks and their alterations in pathogenic states.

https://www.epo.org/en/news-events/european-inventor-award/meet-the-finalists/thomas-tuschl
Thomas Tuschl's groundbreaking method of "switching off" human genes has become a vital tool in developing new ways of diagnosing and treating conditions from haemophilia to high cholesterol. ... The future of RNA based research. Thomas Tuschl is a world‑leading biochemist. He invented a gene‑silencing technique called RNA

https://www.researchgate.net/scientific-contributions/Thomas-Tuschl-15883324
Thomas Tuschl's 25 research works with 2,413 citations and 5,695 reads, including: In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological

https://www2.rockefeller.edu/research/faculty/labmembers/ThomasTuschl/
Research Areas. Chemical and Structural Biology; Genetics and Genomics; Immunology, Virology, and Microbiology ... M.D. and Margaret Al Akl Professor Laboratory of RNA Molecular Biology Laboratory of RNA Molecular Biology. Akat, Kemal Visiting Fellow E-mail: ... Ashley.Searles@rockefeller.edu Tuschl, Thomas Professor Head of Laboratory E-mail:

https://pubmed.ncbi.nlm.nih.gov/33816449/
RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively simple to manufacture, and can target previously undruggable pathways. It is a disruptive therapeutic technology, as small biotech startups, as

https://www.rockefeller.edu/research/2224-tuschl-laboratory-2/
Clinical Research and the Rockefeller University Hospital. Clinical Research Studies. Scientific Publications. ... Laboratory of RNA Molecular Biology. Thomas Tuschl, Ph.D. F. M. Al Akl, M.D. and Margaret Al Akl Professor ... Tuschl Laboratory. News June 20, 2024. Light-weight microscope captures large-scale brain activity of mice on the move

https://www.nature.com/articles/421220a
RNAi-based loss-of-function screens like these 1,2 are tremendously powerful. Yet they have some disadvantages compared with classical genetic screening. ... Thomas Tuschl. ... Tuschl, T. RNA sets

https://www.epo.org/mobile/news-events/events/european-inventor/finalists/2014/tuschl.html
Thomas Tuschl's groundbreaking method of "switching off" human genes has become a vital tool in developing new ways of diagnosing and treating conditions from haemophilia to high cholesterol. ... Tuschl's research exploited the specific function and behaviour of ribonucleic acids (RNA), which regulate the amount of proteins created in a

https://www.helmholtz.de/en/newsroom/article/on-the-trail-of-rna/
He decided to write to Thomas Tuschl, and sent the email that would shape his future career. RNA is universal in biochemistry, whether in animals, plants or microorganisms. Mathias Munschauer's current research focuses on RNA viruses that cause disease, with influenza and coronaviruses being two such RNA viruses.

https://edition.cnn.com/2024/06/05/science/thomas-r-cech-nobel-prize-scn-cec/index.html
In his new book "The Catalyst," Thomas R. Cech talks about the Covid-19 vaccines, what RNA means for future health crises and how gene editing with CRISPR factors in.

https://www.umass.edu/engineering/news/perry-rna-nih
Recent scientific advances have harnessed RNA to develop technologies and therapeutics such as small interfering RNA-based drugs and messenger RNA-based vaccines against cancers and infectious diseases. RNA is composed of thousands of bases, and, like DNA, RNA has four of them: A, C and G, but, instead of DNA's T, RNA has the base U.

https://www.rockefeller.edu/our-scientists/uploads/www.rockefeller.edu/sites/4/2023/05/Tuschl_Profile.pdf
The Tuschl lab has developed approaches to precisely define the binding sites of RNPs and RBPs on RNA and its precursors. Past studies focused on characterizing RBPs implicated in genetic diseases such as fragile X syndrome as well as those with unknown functions. Current studies identify RBPs and the enzymes required for ribosome-associated

https://pubmed.ncbi.nlm.nih.gov/16929310/
Small interfering RNAs (siRNAs) have been widely exploited for sequence-specific gene knockdown, predominantly to investigate gene function in cultured vertebrate cells, and also hold promise as therapeutic agents. Because not all siRNAs that are cognate to a given target mRNA are equally effective, computational tools have been developed based

https://www.genengnews.com/insights/epo-decision-utah-litigation-show-tuschl-patents-remain-mired-in-litigation/
The parties agreed that Max Planck should oversee future prosecution of Tuschl I and Tuschl II in the U.S., and continue to lead the prosecution of Tuschl II outside the U.S. UMass received the

https://biosignaling.biomedcentral.com/articles/10.1186/s12964-024-01724-5
PIWI-interacting RNA (piRNA) is the most abundant small non-coding RNA in animal cells, typically 26-31 nucleotides in length and it binds with PIWI proteins, a subfamily of Argonaute proteins. Initially discovered in germ cells, piRNA is well known for its role in silencing transposons and maintaining genome integrity. However, piRNA is also present in somatic cells as well as in

https://www.rockefeller.edu/news/1650-tenure-awarded-to-rna-researcher-thomas-tuschl/
Thomas Tuschl, a Rockefeller University biochemist interested in the mechanisms by which RNA can regulate genes, has been awarded tenure and promoted to professor.The university's board of trustees approved the appointment earlier this year. "Rockefeller is known for its bold and innovative research and Tom has not only flourished in this environment but has become an influential leader

https://www.science.org/content/podcast/targeting-crop-pests-rna-legacy-temporary-streams-and-future-money
Finally, the next segment in our books series on a future to look forward to. Books host Angela Saini talks with author Rachel O'Dwyer about her recent book Tokens: The Future of Money in the Age of the Platform. They'll discuss new and old ideas of currency, and what it means to have our identities tied to our money as we move toward a

https://www.rockefeller.edu/news/29637-covid-19-vaccines-emerge-search-antiviral-drugs-continues/
The most promising, based on their current inhibitor "hit list," was NSP14, which serves as a lynchpin in a process known as RNA capping. "As a potential drug target, it is especially attractive," Tuschl says, "since disabling the virus' capping mechanism could have the dual effect of curtailing the spread of the virus and also